Doctors for Drug Policy Reform

Last updated
Doctors for Drug Policy Reform
AbbreviationD4DPR
FormationSeptember 30, 2015;8 years ago (2015-09-30)
Type NGO
PurposeEvidence-based drug policies that support public health, human rights, social justice, and consumer protections
Headquarters Washington, DC
Region served
International
President
Bryon Adinoff, MD, DLFAPA, DFAAAP
Key people
 David L. Nathan, MD, DFAPA (founder and past president)
Website d4dpr.org

Doctors for Drug Policy Reform, or D4DPR (formerly known as Doctors for Cannabis Regulation, or DFCR) is a 501(c)(3) non-profit organization that serves as a global voice for licensed health professionals and scientists advocating for evidence-based drug policies and best practices that advance public health, reduce stigma, and minimize harm. D4DPR leverage the expertise, compassion, and influence of licensed health professionals to enact changes in drug policy necessary to improve public health, human rights, social justice, and consumer protections. [1] D4DPR, formerly DFCR, was founded in 2015 by David L. Nathan. In 2021, Dr. Bryon Adinoff, an addictionologist, researcher, and editor-in-chief of the American Journal of Drug and Alcohol Abuse succeeded Nathan to become D4DPR's second president. [2]

Contents

Over the years, DFCR and D4DPR have had notable leaders, spokespeople, and subject matter experts, including Chris Beyrer, Joycelyn Elders, Lester Grinspoon, Peter Grinspoon, Carl Hart, Julie Holland, David C. Lewis, Ethan Nadelmann, David Nutt, Beny Primm, Andrew Solomon, Andrew Weil, and Ken Wolski. [3] [4]

Testimony and media appearances

Board members, spokespeople, and a panel of experts work to change drug policy through public testimony, lectures, op-eds, media appearances, research, and support for legislation individually and as part of larger coalitions. [5] Testimony has been given to legislators in Alabama, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Kansas, Maryland, Massachusetts, Montana, New Hampshire, New Jersey, New York, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Vermont, Virginia, and the United States House of Representatives. [6] On July 10, 2019, David L. Nathan testified before a subcommittee of the United States House Judiciary Committee in support of cannabis legalization. [7] [8]

D4DPR physicians have appeared in dozens of media outlets worldwide. [9] DFCR's first major coverage came in April 2016 by The Washington Post where it made a notable break from other medical professional organizations by endorsing the legalization of cannabis for adult consumption, arguing that prohibition does far more harm to the public than good. [10]

In 2017 David L. Nathan and D4DPR honorary board members, former Substance Abuse and Mental Health Services Administration clinical director H. Westley Clark and former U.S. Surgeon General Joycelyn Elders, co-published a landmark op-ed supporting cannabis legalization in the American Journal of Public Health titled "The Physicians' Case for Marijuana Legalization." [11] [12]

New York Governor Andrew Cuomo directed the state's Department of Health in 2018 to "conduct a study in consultation with other state agencies to review, including but not limited to, the health, criminal justice and economic impacts of a regulated marijuana program in the state of New York, including the implications for the state of New York resulting from marijuana legalization in surrounding states." The resulting commission report cited DFCR's Declaration of Principles and found that regulating cannabis "reduces risks and improves quality control and consumer protection." [13] [14]

NFL campaign

In 2017, DFCR launched a campaign with numerous current and former NFL players to change cannabis policy in the National Football League. [15] As part of its initiative, DFCR worked with former NFL running back Mike James to file the first therapeutic use exemption with the league in May 2018, though it was ultimately denied. [16] In April 2020 the NFL changed its policy regarding cannabis after signing a new collective bargaining agreement with the National Football League Players Association, decreasing but not eliminating penalties for players. [17]

International Intoxicating Cannabinoid Product Symbol and ASTM D8441

In collaboration with standards organization ASTM International, D4DPR created the International Intoxicating Cannabinoid Product Symbol (IICPS), which was designed by Nathan and University of Pennsylvania design student Eli Nathan. Committee D37 of ASTM International approved the IICPS as the world's first and only cannabis product symbol to bear the designation of an international voluntary consensus standard. The standard was published as ASTM D8441 in February 2022. [18] As of mid-2023, the IICPS had been incorporated into the universal symbols required for cannabis packages in the states of Montana, New Jersey, South Dakota and Vermont. [19] [20] [21] [22]

2023 expansion and name change

In October 2023, DFCR announced its rebrand under a new name, Doctors for Drug Policy Reform (D4DPR), empowering the organization to address a wider range of drug policy issues beyond cannabis. D4DPR's goals include maximizing health and wellness, harm reduction, and the legalization of both cannabis and psychedelics. [23]

Following D4DPR's expansion, the non-profit organization International Doctors for Healthier Drug Policies merged with D4DPR under the name of the latter. [24]

See also

Related Research Articles

<span class="mw-page-title-main">Medical cannabis</span> Marijuana used medicinally

Medical cannabis, or medical marijuana (MMJ), is cannabis and cannabinoids that are prescribed by physicians for their patients. The use of cannabis as medicine has not been rigorously tested due to production and governmental restrictions, resulting in limited clinical research to define the safety and efficacy of using cannabis to treat diseases.

<span class="mw-page-title-main">Marijuana Policy Project</span> American organization

The Marijuana Policy Project (MPP) is the largest organization working solely on marijuana policy reform in the United States in terms of its budget, number of members, and staff.

<span class="mw-page-title-main">Removal of cannabis from Schedule I of the Controlled Substances Act</span> Proposed changes to the legal status of cannabis in U.S. federal law

In the United States, the removal of cannabis from Schedule I of the Controlled Substances Act is a proposed legal and administrative change in cannabis-related law at the federal level. It has been proposed repeatedly since 1972. The category is the most tightly restricted category reserved for drugs that have "no currently accepted medical use."

<span class="mw-page-title-main">Legalization of non-medical cannabis in the United States</span> Legalization of marijuana in the United States

In the United States, the non-medical use of cannabis is legalized in 24 states and decriminalized in 7 states, as of November 2023. Decriminalization refers to a policy of reduced penalties for cannabis offenses, typically involving a civil penalty for possessing small amounts, instead of criminal prosecution or the threat of arrest. In jurisdictions without penalty the policy is referred to as legalization, although the term decriminalization is sometimes used for this purpose as well.

<span class="mw-page-title-main">Legal history of cannabis in the United States</span>

In the United States, increased restrictions and labeling of cannabis as a poison began in many states from 1906 onward, and outright prohibitions began in the 1920s. By the mid-1930s cannabis was regulated as a drug in every state, including 35 states that adopted the Uniform State Narcotic Drug Act. The first national regulation was the Marihuana Tax Act of 1937.

<span class="mw-page-title-main">Drug liberalization</span> Process of reducing drug prohibition laws

Drug liberalization is a drug policy process of decriminalizing or legalizing the use or sale of prohibited drugs. Variations of drug liberalization include: drug legalization, drug re-legalization and drug decriminalization. Proponents of drug liberalization may favor a regulatory regime for the production, marketing, and distribution of some or all currently illegal drugs in a manner analogous to that for alcohol, caffeine and tobacco.

<span class="mw-page-title-main">Cannabis in the United States</span> Legality, use, culture, market and production of cannabis in the United States

The use, sale, and possession of cannabis containing over 0.3% THC by dry weight in the United States, despite laws in many states permitting it under various circumstances, is illegal under federal law. As a Schedule I drug under the federal Controlled Substances Act (CSA) of 1970, cannabis containing over 0.3% THC by dry weight is considered to have "no accepted medical use" and a high potential for abuse and physical or psychological dependence. Cannabis use is illegal for any reason, with the exception of FDA-approved research programs. However, individual states have enacted legislation permitting exemptions for various uses, including medical, industrial, and recreational use.

<span class="mw-page-title-main">Marijuana Control, Regulation, and Education Act</span> Bill in the U.S. state of California

The Marijuana Control, Regulation, and Education Act, also known as California Assembly Bill 390 and later Assembly Bill 2254, is the first bill ever introduced to regulate the sale and use of marijuana in the U.S. state of California. If passed and signed into law, marijuana would be sold and taxed openly to adults age 21 and older in California. Tom Ammiano, a Democrat representing California's 13th State Assembly district, introduced this piece of legislation on February 23, 2009, arguing that the bill will "tax and regulate marijuana in a manner similar to alcohol." As introduced, this proposal is estimated to raise over $1 billion in annual revenue by taxing the retail production and sale of marijuana for adults 21 years of age and older. To obtain a commercial grow license one would pay an initial $5,000 fee, then a $2,500 fee each year after that. A tariff of $50 per ounce would also be placed on all sold and grown marijuana. The bill has gained much media attention, statewide and nationally.

<span class="mw-page-title-main">Medical cannabis in the United States</span> Use of cannabis for medical purposes in the United States

In the United States, the use of cannabis for medical purposes is legal in 38 states, four out of five permanently inhabited U.S. territories, and the District of Columbia, as of March 2023. Ten other states have more restrictive laws limiting THC content, for the purpose of allowing access to products that are rich in cannabidiol (CBD), a non-psychoactive component of cannabis. There is significant variation in medical cannabis laws from state to state, including how it is produced and distributed, how it can be consumed, and what medical conditions it can be used for.

<span class="mw-page-title-main">Cannabis political parties</span> Political parties advocating cannabis legalization

Cannabis political parties are generally single-issue parties that exist to oppose the laws against cannabis.

<span class="mw-page-title-main">Legality of cannabis by U.S. jurisdiction</span>

In the United States, the use and possession of cannabis is illegal under federal law by way of the Controlled Substances Act of 1970. Cannabis is classified as a Schedule I drug under the Controlled Substances Act, determined to have a high potential for abuse and no accepted medical use, prohibiting its use for any purpose. Despite this policy, most states have passed laws to legalize the use of cannabis for medical purposes, while 24 of 50 states have legalized for recreational use.

<span class="mw-page-title-main">Timeline of cannabis laws in the United States</span> Historical list in chronological order of U.S. cannabis law

The legal history of cannabis in the United States began with state-level prohibition in the early 20th century, with the first major federal limitations occurring in 1937. Starting with Oregon in 1973, individual states began to liberalize cannabis laws through decriminalization. In 1996, California became the first state to legalize medical cannabis, sparking a trend that spread to a majority of states by 2016. In 2012, Washington and Colorado became the first states to legalize cannabis for recreational use.

David L. Nathan is an American psychiatrist, writer, and founder and past president of Doctors for Cannabis Regulation. Best known for his advocacy of cannabis legalization, he has also published research in the academic and lay press on a range of other topics, including archeology, numismatics, the history of animation and early American football.

<span class="mw-page-title-main">Effects of legalized cannabis</span> Economic and societal effects of legalized cannabis

The use of cannabis as a recreational drug has been outlawed in many countries for several decades. As a result of long-fought legalization efforts, several countries such as Uruguay and Canada, as well as several states in the US, have legalized the production, sale, possession, and recreational and/or medical usage of cannabis. The broad legalization of cannabis in this fashion can have numerous effects on the economy and society in which it is legalized.

<span class="mw-page-title-main">Glossary of cannabis terms</span>

Terms related to cannabis include:

Cannabis product testing is a form of product testing analyzes the quality of cannabis extracts, edibles, and THC and CBD levels in an emergent consumer market eager to sell adult use products. Analytical chemistry and microbiology laboratories are important entities in consumer protection. These labs not only determine the condition and viability of cannabinoids, water content, heavy metals, pesticides, terpenes, yeast, but also the presence of mold, mycotoxins, and solvents. These laboratories emerged when advocates of cannabis testing raised concerns about potential contaminants.

<span class="mw-page-title-main">Michael Krawitz</span> US Air force veteran

Michael Alan Krawitz is a US Air force veteran, Executive Director of the non-profit Veterans for Medical Cannabis Access, researcher on the history of medical cannabis, and international advocate for cannabis policy reform with FAAAT think & do tank and the International Association for Cannabinoid Medicines.

<span class="mw-page-title-main">ASTM D8441/D8441M</span> Standard defining a symbol for cannabis products

ASTM D8441 is an ASTM International standard defining the International Intoxicating Cannabinoid Product Symbol (IICPS). As of mid-2022, the symbol has been incorporated into the universal symbols required for cannabis packages in the states of Montana, New Jersey, South Dakota and Vermont.

References

  1. ↑ "Home". Doctors for Drug Policy Reform. Retrieved 2023-12-01.
  2. ↑ "D4DPR Announces Dr. Bryon Adinoff as President". Doctors for Drug Policy Reform. Retrieved 2023-12-01.
  3. ↑ "Leadership". Doctors for Drug Policy Reform. Retrieved 2023-12-01.
  4. ↑ "D4DPR Experts". Doctors for Drug Policy Reform. Retrieved 2023-12-01.
  5. ↑ Amanda Hoover | NJ Advance Media For NJ. com (2020-10-02). "More groups voice support — and opposition — to the legal weed ballot question". nj. Retrieved 2020-10-08.
  6. ↑ "D4DPR Expert Testimony". Doctors for Drug Policy Reform. Retrieved 2023-12-01.
  7. ↑ "Marijuana Laws in America: Racial Justice and the Need for Reform | U.S. House of Representatives Judiciary Committee". judiciary.house.gov. Retrieved 2020-10-08.
  8. ↑ "DFCR Founder David L. Nathan testifies at the first U.S. Congressional Committee Hearing on Cannabis Legalization". Doctors for Drug Policy Reform. 2019-07-10. Retrieved 2023-12-01.
  9. ↑ "Media (selected)". Doctors for Drug Policy Reform. Retrieved 2023-12-01.
  10. ↑ "More and more doctors want to make marijuana legal". The Washington Post. 2016-04-15. Retrieved 2023-12-01.
  11. ↑ Nathan, David L.; Clark, H. Westley; Elders, Joycelyn (2017-10-11). "The Physicians' Case for Marijuana Legalization". American Journal of Public Health. 107 (11): 1746–1747. doi:10.2105/AJPH.2017.304052. ISSN   0090-0036. PMC   5637675 . PMID   29019777.
  12. ↑ "The Physicians' Case for Cannabis Legalization". Doctors for Drug Policy Reform. 2017-07-27. Retrieved 2023-12-01.
  13. ↑ "Regulated Marijuana". www.health.ny.gov. Retrieved 2020-10-08.
  14. ↑ "Assessment of the Potential Impact of Regulated Marijuana in New York State" (PDF). New York Department of Health. Retrieved 2020-10-07.
  15. ↑ "ESPN to Cover Cannabis in Professional Sports Event in Houston During the Week of the Big Game". PR Log, January 20, 2017.
  16. ↑ Maese, Rick. "An NFL running back says he needs one thing to continue his football career: Weed". chicagotribune.com. Retrieved 2020-10-08.
  17. ↑ Belson, Ken (2020-04-16). "N.F.L. Bows to Marijuana's New Status". The New York Times. ISSN   0362-4331 . Retrieved 2020-10-08.
  18. ↑ "New Standard Provides International Symbol for Intoxicating Cannabinoids.” ASTM International News Release, March 15, 2022. https://newsroom.astm.org/new-standard-provides-international-symbol-intoxicating-cannabinoids
  19. ↑ Montana Department of Revenue, General Labeling Requirements, accessed December 1, 2023. https://mtrevenue.gov/cannabis/labeling-and-packaging/
  20. ↑ NJ Cannabis Regulatory Commission, Business Resources, accessed December 1, 2023. https://www.nj.gov/cannabis/businesses/resources/
  21. ↑ Medical Cannabis in South Dakota, "Standard Cannabis Product Symbol," accessed December 1, 2023. https://medcannabis.sd.gov/Establishments/Symbol.aspx
  22. ↑ State of Vermont Cannabis Control Board, Rule 2: Regulation of Cannabis Establishments, November 2021. https://ccb.vermont.gov/sites/ccb/files/2021-11/Proposed%20Rule%202%20-%20Regulation%20of%20Cannabis%20Establishments.pdf
  23. ↑ "Doctors for Cannabis Regulation Rebrands as Doctors for Drug Policy Reform". PR Log, October 2, 2023.
  24. ↑ "International Doctors for Healthier Drug Policies". IDHDP.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.